Interestingly, KRASG12X NSCLC models with loss of expression of CDKN2A (CDKN2A loss) exhibited a significantly shorter PFS on RMC-6236 treatment as compared with those with intact CDKN2A expression. The gene discussed is CDKN2A; the disease is non-small cell lung carcinoma.